Success Metrics

Completion Rate

0%(0/1)

Active Trials

4(50%)

Terminated

1(13%)

Phase Distribution

Ph phase_2

63%

Ph phase_3

13%

Ph phase_1

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

2(25.0%)

Phase 2Efficacy & side effects

5(62.5%)

Phase 3Large-scale testing

1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(5)

Terminated(1)

Other(2)

Detailed Status

Recruiting3

unknown2

Not yet recruiting1

Terminated1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 3

Trials by Phase

Phase 12 (25.0%)

Phase 25 (62.5%)

Phase 31 (12.5%)

Trials by Status

not_yet_recruiting113%

terminated113%

recruiting338%

active_not_recruiting113%

unknown225%

Recent Activity

4 active trials

Showing 5 of 8

recruitingphase_3

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

NCT05512364

not_yet_recruitingphase_1

E.N.D.E.A.V.O.R.: An Exemestane Needed Dose Efficacy and Verification as an Ovulation Induction Regimen Study

NCT07706374

recruitingphase_1

Sapu003 in Advanced mTOR-sensitive Solid Tumors

NCT07369505

active_not_recruitingphase_2

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

NCT05150652

recruitingphase_2

Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.

NCT06364267

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT05512364Phase 3

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

Recruiting

NCT07706374Phase 1

E.N.D.E.A.V.O.R.: An Exemestane Needed Dose Efficacy and Verification as an Ovulation Induction Regimen Study

Not Yet Recruiting

NCT07369505Phase 1

Sapu003 in Advanced mTOR-sensitive Solid Tumors

Recruiting

NCT05150652Phase 2

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

Active Not Recruiting

NCT06364267Phase 2

Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.

Recruiting

NCT03874325Phase 2

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Terminated

NCT03024580Phase 2

A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer

Unknown

NCT02646735Phase 2

Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients

Unknown

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8